Participated · Seed · Jan 2026

Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.

Participated · Equity · Sep 2025

Founded in 2015, Belgium-headquartered Sunrise Group pairs FDA-cleared sleep-diagnostic hardware—most notably its mandibular movement sensor—with a full-stack software platform to power Dreem Health, its U.S. digital sleep clinic. Patients connect online with licensed sleep specialists who diagnose and treat conditions such as sleep apnea and insomnia entirely from home and with insurance coverage. Sunrise has regulatory clearances in all 50 states, contracts with payors that collectively insure more than 170 million Americans, and a clinical network exceeding 500 referring providers. The company operates with a team of 80+ clinicians, engineers, and researchers and positions its integrated tech-and-care model as a scalable answer to the severe shortage of sleep physicians. Revenue figures were not disclosed, but the firm secured a $29 million capital infusion to fund nationwide expansion and next-generation hardware and software development. Future plans include enlarging clinical services, accelerating U.S. market penetration, and continuing R&D on detection, monitoring, and treatment technologies for a broad range of sleep disorders.

Participated · Equity · Jan 2025

Trustup operates a platform connecting individuals with certified construction and renovation professionals and offers a software solution for independent contractors to manage quotes, invoicing and project tracking. Founded in 2017 by CEO Sébastien Remacle and based in Liège, Belgium, the company employs over 55 people. It raised €5M in funding on January 15, 2025. The company intends to use the proceeds to recruit an additional 50 employees in Belgium to support international growth, with a priority focus on strengthening its presence in Flanders. The platform emphasizes contract security and customer satisfaction while helping professionals streamline administration and project management. Backers included Rise PropTech Fund, Brick & Mortar Ventures, Noshaq, InvestSud and private investors.

Participated · Series A · Sep 2024

Brenus Pharma is advancing an off-the-shelf platform in immuno-oncology that mimics tumor protein expression to make tumors visible to the immune system. Its lead clinical-stage asset is STC-1010 (NCT06934538), targeting MSS metastatic colorectal cancer, and recent execution across clinical, regulatory and business development milestones has been highlighted by the company. Brenus positions its technology for multi-asset expansion and plans to use new capital to complete the Phase I program for STC-1010 and to advance its next drug candidate. The company has raised a total of €38 million since inception following the €11 million Series A extension. The firm announced the financing from Lyon, France and continues engaging both existing and new international investors to support its development plans.

Participated · Equity · Jun 2024

Myocene has developed an AI-based device that computes a muscle fatigue index in about two minutes. The system uses a dedicated algorithm to analyse measurements obtained via electrostimulation for force sensors and very controlled muscle contractions. The device can be used indoors and outdoors to help top-level athletes and coaches manage fatigue, adapt training and rest periods, and reduce risks of overtraining and injury. Since the prior round in March 2023 the company has signed contracts with clubs including OGC Nice, Sporting Club Braga and Paris Saint-Germain; more than 850 sportsmen and women have used it and over 10,500 measurements were taken, and the device has been tested by almost 1,500 athletes. Myocene raised €3 million in funding that was partly equity/capital and partly a convertible loan; investors include InvestSud, Wallonie Entreprendre, Belgian public investor Noshaq and the historical founders. The company plans to use the funds to accelerate commercialisation in Europe and to launch in the US in 2025. Myocene develops sports-technology devices that leverage patented algorithms and AI to measure athletes’ muscle fatigue and performance. Its products are designed to help teams and athletes better design training, avoid overtraining and reduce accidents tied to long-term muscular fatigue. The company is led by Dr Pierre Rigaux, Chairman and Founder. Myocene completed a €2M bridge funding round comprised of capital and a convertible loan. Backers included Wallonie Entreprendre, Noshaq and the company’s historical founders. The firm intends to use the funds to finalize a market-ready product expected mid-2024.